Glucocorticoids are the standard treatment to treat inflammation in asthma, however, they are often associated with cardiovascular disease, osteoporosis or immune suppression risk with chronic use. Novel strategies to combine with traditional treatments, such as those intended to restore hydrogen sulfide (H2S) levels, have emerged as options for treating severe uncontrolled asthma with frequent exacerbations.
Addex Therapeutics Ltd. and Indivior plc have announced the selection of clinical candidates from their γ-aminobutyric acid subtype B (GABA-B) positive allosteric modulator (PAM) research collaboration.
Immorna Biotherapeutics Inc. has received a grant from the Bill & Melinda Gates Foundation to support the clinical development of JCXH-108, a monovalent respiratory syncytial virus (RSV) vaccine based on Immorna’s proprietary mRNA and ready-to-use (RTU)-lipid nanoparticle (LNP) technologies.
Human rhinoviruses (hRVs) are associated with upper respiratory tract infections such as the common cold, otitis media or sinusitis. In immunocompromised individuals or older people, hRVs can exacerbate existing pulmonary conditions such as asthma or chronic obstructive pulmonary disease.
Reistone Biopharma Co. Ltd. has described phosphodiesterase PDE4B1 inhibitors reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease, acute respiratory distress syndrome, atopic dermatitis, overactive bladder, psoriasis, ulcerative colitis and urticaria, among others.
Beijing Primegene Therapeutics Co. Ltd. has identified azacycloalkane compounds acting as rho kinase 1 (ROCK1; p160-ROCK) and/or rho-associated protein kinase 2 (ROCK 2) inhibitors reported to be useful for the treatment of asthma, cancer, insulin resistance, neurodegeneration, osteoporosis and renal failure.
Airna Corp. Inc., of Cambridge, Mass., announced it has closed an oversubscribed $60 million financing round, bringing its total series A funding to $90 million.
Intellia Therapeutics Inc. has received clearance from the U.K. Medicine and Healthcare products Regulatory Agency (MHRA) to initiate a phase I/II study of NTLA-3001 for the treatment of α1-antitrypsin deficiency (AATD)-associated lung disease.
GSK plc and Flagship Pioneering Inc. have entered a collaboration to discover and develop a portfolio of therapeutics and vaccines for respiratory and immunology indications.
Cigarette smoke, the main cause of chronic obstructive lung disease, is considered a significant contributor of neuroinflammation, potentially leading to cognitive impairment and neurodegeneration. About 61% of individuals with chronic obstructive pulmonary disease have neurocognitive dysfunction.
RSS
